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Abstract
Background: The aim of this study was to determine
whether haptoglobin (Hp) genotypes are associated
with prognosis in patients with squamous cell carci-
noma of the head and neck (HNSCC).
Methods: We studied patients with HNSCC without
distant metastasis at diagnosis. The Hp genotype of
each patient was determined and the prognostic
significance of the Hp genotype was further analyzed.
Pearson’s x2-test or Fisher’s exact test were used to
analyze correlations between Hp genotype and clini-
cal characteristics of HNSCC. Eighty patients with
newly diagnosed HNSCC who were treated with
curative modality were enrolled in this study. Kaplan-
Meier plots and log-rank test were used to compare
locoregional recurrence-free survival, distant-metas-
tasis-free survival and overall survival of patients
according to Hp genotype. Survival analysis was
performed using Cox proportional hazard models.
Results: Eighty patients with newly diagnosed HNSCC
were enrolled in this study. There was no significant
difference in the distribution of Hp genotypes in
HNSCC patients and healthy individuals (ps0.959).
Matched-pair analysis showed that locoregional
recurrence-free survival was poor (ps0.02) for
HNSCC patients with Hp 2-2 or 2-0. There was no sig-
nificant difference in distant metastasis-free survival
and overall survival (ps0.422 and 0.509, respective-
ly). Multivariate analysis showed that Hp 2-2 or 2-0
was associated with an increased risk of locoregional
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recurrence wHazard ratio (HR) 5.9; 95% confidence
interval (CI), 1.1–6.65; ps0.038x. The risk was still
higher in patients with Hp 2-2 or 2-0 after further
adjusting for age and treatment modality (HR 7.6; 95%
CI, 1.2–46; ps0.028) in locoregional recurrence-free
survival.
Conclusions: The present data show that the Hp
genotype is closely related to recurrence rate in
patients with HNSCC. Patients with Hp 2-2 or 2-0 have
greater locoregional recurrence and significantly
increased HRs in multivariate analysis. The Hp geno-
type may be a prognostic factor in patients with
HNSCC.
Clin Chem Lab Med 2009;47:1277–83.
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Introduction
Squamous cell carcinoma of the head and neck
(HNSCC) is one of the most common cancers world-
wide that occurs predominantly in middle-aged and
older men who use tobacco, alcohol, and betel nuts.
In Taiwan, the incidence of HNSCC has continued to
increase and is currently the fourth most common
cause of cancer-related mortality in men (1). HNSCC
has a high recurrence rate and poor survival. The
prognosis and clinical outcomes of patients with
HNSCC depends primarily on the TNM staging sys-
tem. However, the most popular and widely used
TNM system does not always predict prognosis well.
Reliable prognostic factors may be used to supple-
ment the present staging system.
Haptoglobin (Hp), a hepatocyte-derived serum a2-
glycoprotein, is an acute-phase reactant produced in
response to inflammatory cytokines and glucocorti-
costeroids (2, 3). Previous studies have shown that
Hp may play an important role in host defense against
infection and neoplasms by decreasing the availabi-
lity of iron to invading pathogens and tumor cells, and
by modulating angiogenesis and other inflammatory
processes (4, 5). The expression of Hp is controlled
by the polymorphic Hp locus located on chromosome
16q22. The characteristics of Hp vary according to the
different Hp genotypes. Hp 1-1 is a much better anti-
oxidant compared with HP 2-2 or HP 2-0, and binds
more strongly with free hemoglobin (3, 6, 7). Angio-
genic effects are more frequently observed with Hp
2-2, while Hp 2-1 has an intermediate characteristic
(8, 9).
Several studies have investigated the relationship
between Hp concentrations and head and neck cancer
(10, 11). However, there are no published data on the
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prognostic influence of Hp genotypes in HNSCC. The
goal of this study was to investigate the prognostic
influence of Hp genotypes in HNSCC.
Materials and methods
Human subjects
The study was conducted with the approval of the Human
Research Ethics Committees of our institution. Written
informed consent was obtained from all patients with
HNSCC and healthy individuals between 2005 and 2008. A
total of 92 cases were identified and retrieved from the
archives. Twelve patients were not eligible for analyses
because of the presence of distant metastasis at the time of
presentation and loss of follow-up. In this study, healthy
subjects, who were asymptomatic and underwent physical
examination, chest X-ray, abdominal sonogram for reasons
of promoting good health and disease prevention during
annual health check-up were recruited as control subjects.
All blood samples were collected in EDTA-containing tubes.
A total of 80 HNSCC patients for whom complete data sets
were available were analyzed. The following data were
recorded for each patient: age, gender, tobacco use, alcohol
use, betel nut chewing, treatment modality, and outcome.
All tumors were staged according to the American Joint
Committee on Cancer (AJCC) system, modified in 2002.
All patients initially received curative treatment. On com-
pletion of treatment, patients were followed regularly every
month during the first year, every 2 months in the second
year and every 3 months thereafter. Chest X-rays were per-
formed annually, while head and neck magnetic resonance
imaging/computed tomography, bone scans and ultrasound
of abdomen were performed when clinically indicated.
Hp genotyping based on polymerase chain
reaction (PCR)
Genomic DNA was extracted from peripheral blood mono-
nuclear cells using a DNA extraction kit (Qiagen, Valencia,
CA, USA). PCR methods were used to analyze the Hp 1 and
Hp 2 alleles as described previously (12, 13). Primers Hp-del-
U and Hp-del-L were used for amplification of a 315-base
pair (bp) Hp 0 allele-specific sequence. Primers Hp-exon-U
and Hp-exon-L were used to amplify a 476-bp Hp 1 or Hp 2
allele-specific sequence (14, 15). PCR was carried out in a
final volume of 50 mL containing 10–20 ng of genomic DNA.
For protocol 1, 1= PCR buffer (Qiagen), 1.5 mM MgCl2,
0.2 mM dNTPs, 0.4 mM of each primer, and 2 units of Qiagen
tag DNA polymerase were included in the PCR reactions
using primers A and B. The program for PCR using primers
A and B was as follows: an initial incubation at 958C for
5 min, 35 cycles of incubation at 958C for 1 min, 668C
for 40 s, and 728C for 90 s, with a final extension at 728C for
10 min. For protocol 2, 1= PCR buffer (Qiagen), 1.5 mM
MgCl2, 0.05 mM dNTPs, 0.2 mM of each primer, and 2 units
of ABgene tag DNA polymerase were included in the PCR
reactions using primers C and D. For the PCR with primers
C and D, the program was as follows: an initial incubation
at 958C for 5 min, 35 cycles of incubation at 958C for 1 min,
698C for 1 min, with a final extension at 728C for 10 min.
For PCR protocol 3, 1= PCR buffer (Qiagen), 1.5 mM MgCl2,
0.2 mM dNTPs, 0.2 mM of each primer, and 2 units of Qiagen
taq DNA polymerase were included in the PCR reactions. The
thermal cycler conditions used for amplification were as fol-
lows: an initial incubation at 958C for 5 min, 35 cycles of
incubation at 958C for 30 s, 608C for 40 s, and 728C for 1 min,
with a final extension at 728C for 10 min. The resulting PCR
products underwent electrophoresis in 1% agarose gel
stained with ethidium bromide. All patient samples were
analyzed using protocol 1 with primers A and B. If the pres-
ence of the 1757-bp product was detected, the samples were
later analyzed according to protocol 2 with primers C and D.
The Hp 0-specific PCR product was detected as a 315-bp
band, whereas the product of Hp exon 1 was detected as a
476-bp band. The sequences of primers were:
A: 59-GAGGGGAGCTTGCCTTTCCATTG-39
B: 59-GAGATTTTTGAGCCCTGGCTGGT-39
C: 59-CCTGCCTCGTATTAACTGCACCAT-39
D: 59-CCGAGTGCTCCACATAGCCATGT-39
Hp-del-U: 59-CTTTATGGCACTGGGGAACAAGCATTTTG-39
Hp-del-L: 59-CAGGAAGAGATTTTTAGCCGTGGTCAGCAG-39
Hp-exon-U: 59-GCAGTGTGAAAATCCTCCAAGATAA-39
Hp-exon-L: 59-AATTTAGCCCATTTGCCCGTTTCTT-39.
Analyzing survival rates with matched-pair method
In order to limit the effect of confounders and to increase
statistical efficiency, a matched-pair method was conducted.
Previous studies showed that patients with nasopharyngeal
carcinoma and breast cancer who had the Hp 1-1/2-1 geno-
type had a better prognosis (16, 17). Due to these observa-
tions, we assigned HNSCC patients into two groups: patients
with Hp 1-1 or 2-1 and patients with Hp 2-2 or 2-0. Patients
with Hp 1-1 or 2-1 were matched randomly with patients with
Hp 2-2 or 2-0 in a 1:1 ratio. Matching variables were gender,
site of primary tumor, and the stage of clinical disease.
Statistical analysis
All data were analyzed using the SPSS (Version 12, SPSS
Inc., Chicago, IL, USA) system. The association between dif-
ferent categorical variables was analyzed with Pearson’s
x2-test or Fisher’s exact test. Hardy-Weinberg equilibrium
analyses for Hp polymorphism were conducted with one
degree of freedom in the HNSCC patients and controls. Sur-
vival rates were estimated using the Kaplan-Meier method
and Kaplan-Meier survival curves were compared using the
log-rank test. The Cox proportional regression model was
used to evaluate the effect of Hp genotypes on survival rates
after adjusting for matching variables and other potential
prognostic factors.
Results
The following Hp genotype-specific banding was
obtained: Hp 1-1 and Hp 2-2 were characterized by
single bands representing the 1757- and 3481-bp
products, respectively. Genotype 2-1 was character-
ized by the presence of both the 1757- and 3481-bp
products (Figure 1A). With respect to Hp 2-1, the Hp
1-specific 1757-bp band was generally more intense
than the Hp 2-specific 3481-bp band (Figure 1A, lane
2). Figure 1B shows that patients without the 349-bp
product had the Hp 1-1 genotype (lane 5). Figure 1C
shows the Hp 0 pattern.
Figure 2 shows patient enrollment in this study. A
total of 80 patients with HNSCC with complete data
were enrolled. Also, 80 healthy individuals of similar
age and gender were included as a comparison group
for the distribution of Hp genotypes. The final study
sample of matched-pair analysis consisted of 46
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Figure 1 Haptoglobin genotyping. Agarose gels demon-
strating genotype determinations using DNA from individu-
als representing genotype Hp 1-1, Hp 2-1 and Hp 2-2.
(A) Haptoglobin genotyping with primer A and B (protocol
1). (B) Protocol 2 with primer C and D was used to determine
the complete genotype when the 1757-bp band was detect-
ed. A 349-bp product was generated from the genomic DNA
of individuals homozygous or heterozygous for the Hp 2
allele, whereas no product was formed in the presence of
the Hp 1 allele (lane 5, DNA from the individuals with the Hp
1-1 genotype). (C) Detection of haptoglobin gene deletion.
Both 315-bp and 476-bp bands were amplified from individ-
uals heterozygous for the Hp 0 allele (lanes A and B).
Figure 2 Flow diagram for analysis of genotype distribution
and survival analysis with paired-matching method.
Table 1 Hp genotype distribution in the normal control
group and HNSCC patients.
Variables Control group HNSCC group p-Value
(ns80) (ns80)
Gender
Male 78 (69) 78(69)
Female 2 (31) 2 (31)
Age 0.652
Mean"SD 51"12 52"11
Genotype 0.959
Hp 1-1 8 (10) 8(10)
Hp 2-1 35 (44) 32 (40)
Hp 2-2 33 (41) 35 (44)
Hp 2-0 4 (5) 5 (6)
x2 a,b 2.179 2.5
Alle frequency
Hp 1 0.319 0.3
Hp 2 0.656 0.669
Hp 0 0.025 0.031
Values are given as number (percentage). ax2-test for devi-
ation from Hardy-Weinberg equilibrium; ap-values from
goodness-of-fit x2-test in Hardy-Weinberg equilibrium in the
control group was 0.139, and 0.113 in the HNSCC group.
HNSCC, head and neck squamous cell carcinoma; SD, stan-
dard deviation; Hp, haptoglobin.
patients with HNSCC (44 men, 2 women; mean age,
51 years), 23 patients with Hp 1-1 or 2-1 and 23
patients with Hp 2-1 or Hp 2-0. In each group, there
were 11 patients with oral cancer, four patients with
oropharyngeal cancer, and eight patients with hypo-
pharyngeal cancer.
Association between HNSCC and Hp
genotypes
The first part of the study was comprised of 80
HNSCC patients and 80 healthy individuals. Table 1
shows the distribution of Hp genotypes in healthy
individuals and patients with HNSCC. There was no
significant difference in the distribution of Hp geno-
types between these two groups (ps0.959). The dis-
tribution of genotypes in healthy individuals and
HNSCC patients were in Hardy-Weinberg equilibrium
(ps0.139 and 0.113, respectively).
Association between Hp genotypes and
survival of HNSCC patients
The demographics of the two groups were similar.
There were no significant differences between the
two populations in terms of gender, tobacco use,
alcohol use and betel nut chewing. The patients were
evenly matched with respect to tumor stage, tumor
classification, and nodal status (Table 2). Although the
two groups were not matched with respect to treat-
ment modality, the types of treatment received were
similar.
The time of follow-up ranged from 5 to 60 months
wmean"standard deviation (SD), 21"11.7 months;
median, 21 monthsx for the HNSCC patients with Hp
1-1 or 2-1, and ranged from 4 to 52 months
(mean"SD, 20"10.2 months; median, 19 months) for
the HNSCC patients with Hp 2-2 or 2-0. HNSCC
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Table 2 Characteristics of patients: matching variables.
Genotype p-Value
Hp 1-1, 2-1 Hp 2-2, 2-0
(ns23)a (ns23)b
Gender
Male 22 (96) 22 (96)
Female 1 (4) 1 (4)
Age in years
Mean"SD 52"12 50"11 0.739
Primary site
Oral cavity 11 11
Oropharynx 4 4
Hypopharynx 8 8
Stage
III 1 (4) 1 (4)
IV 22 (96) 22 (96)
T classification 0.562
T2 7 (30) 4 (17)
T3-4 16 (70) 19 (83)
N classification 1
N0-1 7 (30) 7 (30)
N2-3 16 (70) 16 (70)
Treatment 0.475
Surgeryqadjuvant R/T 17 (74) 19 (83)
or adjuvant CCRT
CCRT 6 (26) 4 (17)
Values are given as number (percentage). aFive patients with
Hp 1-1 genotype and 18 patients with Hp 2-1; b20 patients
with Hp 2-2 genotype and three patients with Hp 2-0 geno-
type. Hp, haptoglobin; SD, standard deviation; R/T, radio-
therapy; CCRT, concurrent chemoradiotherapy.
patients with Hp 1-1 or 2-1 had better locoregional
recurrence-free survival rates (ps0.02; Figure 3A).
Table 3 shows the failure patterns of HNSCC patients
with different Hp genotypes. Ten of 23 (44%) HNSCC
patients with Hp 2-2 or 2-0 had locoregional recur-
rence, vs. three of 23 (13%) HNSCC patients with Hp
1-1 or 2-1 (ps0.022). Patients with recurrent tumor
received salvage treatment. Seven of 10 HNSCC
patients with Hp 2-2 or 2-0 received salvage surgery
with or without adjuvant chemoradiotherapy and four
patients were successfully salvaged; three patients
received concurrent chemoradiotherapy for their
recurrent tumor and one patient was successfully sal-
vaged. Two of three HNSCC patients with Hp 1-1 or
2-1 received surgical intervention and neither of these
patients were successfully salvaged; one patient who
received chemotherapy was successfully salvaged.
There was no significant difference with respect to
distant metastasis-free survival and overall survival
rates (ps0.422 and 0.509, respectively). Five of 23
(23%) HNSCC patients with Hp 2-2 or 2-0 had distant
metastasis, vs. seven of 23 (30%) HNSCC patients
with Hp 1-1 or 2-1 (ps0.559); eight of 23 (35%)
patients with Hp 2-2 or 2-0 died, vs. nine of 23 (39%)
patients with Hp 1-1 or 2-1 (ps0.76). Patients with dis-
tant metastasis received palliative treatment. There
was a significant difference in terms of risk of loco-
regional recurrence-free survival between these two
groups after adjusting for gender, tumor site, and
stage wHazard ratio (HR) 5.9; 95% confidence interval
(CI) 1.1–6.65; ps0.038; Table 4x. The risk was still
higher for the patients with Hp 2-2 or 2-0 after further
adjusting for age and treatment modality (HR 7.6; 95%
CI, 1.2–46; ps0.028) with respect to locoregional
recurrence-free survival. The HR was not significantly
increased in distant metastasis-free survival and over-
all survival (ps0.339 and 0.776, respectively; Table 4).
Discussion
The genotypes of Hp can be readily determined
(12–15) using PCR and electrophoresis. Our data dem-
onstrated that the pattern of Hp genotype distribution
in patients with HNSCC was not different from that of
healthy individuals. The distribution of Hp genotypes
in healthy individuals and patients with HNSCC was
in Hardy-Weinberg equilibrium. Although previous
studies showed the relationship between specific Hp
genotypes and cancer, this phenomenon was not
observed in HNSCC (3).
Our previous study showed that Hp 2-2 was a neg-
ative prognostic factor for nasopharyngeal carcinoma
(16). Gast et al. also reported that Hp 2-2 was asso-
ciated with poor survival in breast cancer patients
(17). We divided our HNSCC patients into two groups
because of these studies. With matched-pair analysis,
23 patients with Hp 2-2 or 2-0 were pair-matched by
gender, primary tumor site, and stage to 23 patients
with Hp 1-1 or 2-1. The patient demographics pre-
sented in Table 1 show that the two groups were
similar. The two populations could be compared
with respect to recurrence, distant metastasis, and
overall survival. Figure 3 shows that HNSCC patients
with Hp 2-2 or 2-0 had poor locoregional recurrence
survival rates (ps0.02). Using gender, primary tumor
site, and overall stage as covariates, Hp 2-2 or 2-0 was
an independent prognostic factor for locoregional
recurrence (HRs5.9; ps0.038). The risk was still high-
er in patients with Hp 2-2 or 2-0 after further adjusting
for age and treatment modality (HR 7.6; ps0.028)
with respect to locoregional recurrence-free survival.
Although there was greater recurrence in HNSCC
patients with Hp 2-2 or 2-0, the survival rates were
not statistically significant. Seven of 10 (70%) recur-
rent HNSCC patients with Hp 2-2 or 2-0 underwent
salvage surgery and adjuvant therapy and three
patients received salvage chemoradiotherapy. In the
Hp 2-2/2-0 group, five HNSCC patients with recurrent
tumor were eventually successfully salvaged. This
may be one of the reasons why there was no signifi-
cant difference in survival rates between these two
groups.
Some studies investigated the relationship between
Hp concentrations and both HNSCC and nasopharyn-
geal carcinoma (10, 11). Free hemoglobin promotes
the accumulation of free radicals and other harmful
reactive oxygen species, as well as the breakdown of
erythrocytes in interstitial fluid resulting in hemoglo-
bin-mediated free radical formation (18). Plasma Hp
is a major antioxidant and can protect against hemo-
globin-mediated lipid peroxidation (19). Lim et al. (20)
showed that in Hp knockout mice, more deaths and
renal damage occurred during hemolysis. The refer-
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Figure 3 Survival curves of different haptoglobin genotypes.
(A) Locoregional recurrence-free survival; (B) distant metastasis-free survival; (C) recurrence-free survival and (D) overall
survival in patients with head and neck squamous cell carcinoma with different haptoglobin genotypes.
ence range for Hp is lower in individuals with Hp 2-2
and this may result in reduced protection against free
radicals (6, 21). The antioxidative capacity of body flu-
ids is less efficient in Hp 2-2 individuals. This finding
was attributed to the fact that the Hp 2-2 phenotype
produces higher molecular mass species ()200 kDa)
which restrict their distribution in interstitial fluid (6).
Tseng et al. (7) reported that the ranking of the anti-
oxidant activity was as follows: Hp 1-1)Hp 2-1)Hp
2-2 in an vitro study. Also, transfected Chinese ovary
cell (CHO) with Hp 1-1 expression had increased tol-
erance against oxidative stress than CHO cells
expressing other Hp genotypes. Furthermore, individ-
uals with Hp 2-0 have extremely low concentrations
of Hp (14). Greater locoregional recurrence rates in
HNSCC patients with Hp 2-2 or 2-0 may be partially
attributed to the poor antioxidant capacity of Hp 2-2
and 2-0 type when compared with other Hp types.
Individuals with a Hp 2-2 or 2-0 genotype have
lower Hp concentrations and therefore, less efficient
hemoglobin-binding capacity. This results in some
degree of heme iron accumulation as shown by the
association of Hp 2-2 with higher serum iron, higher
transferrin saturation, and higher serum ferritin con-
centrations (20, 22). Iron promotes neoplastic cell
growth and accumulates in cancer cells more readily
than in normal cells, and excess iron may suppress
the tumoricidal activity of macrophages and interfere
with lymphocyte trafficking (23, 24).
Hp is involved in arterial restructuring by facilitating
cell migration through the accumulation of a tempo-
rary gelatin matrix. It has been suggested that Hpmay
be involved in other vascular and non-vascular pro-
cesses such as angiogenesis and tumor cell invasion
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Table 3 Failure patterns of patients with HNSCC according to Hp genotype.
Genotype p-Value
Hp 1-1, 2-1 Hp 2-2, 2-0
(ns23)a (ns23)b
Failure patterns
Locoregional 3 (13) 10 (44) 0.022
Distant metastasis 7 (30) 5 (23) 0.559
Locoregional and distant metastasis 1 (4) 1 (4) 1
Survival status
Death 9 (39) 7 (30) 0.536
Values are given as number (percentage). aFive patients with Hp 1-1 genotype and 18 patients with Hp 2-1; b20 patients with
Hp 2-2 genotype and three patients with Hp 2-0 genotype. HNSCC, head and neck squamous cell carcinoma; Hp, haptoglobin.
Table 4 HR of locoregional recurrence, distant metastasis and overall death from disease associated with Hp genotype 2-2
or 2-0 vs. Hp genotype 1-1 or 2-1 in head and neck cancer.
Analysis Locoregional recurrence p-Value Distant metastasis p-Value Overall death p-Value
HR (95% CI) HR (95% CI) HR (95% CI)
Cox regression analysis on 5.9 (1.104–6.65) 0.038 0.4 (0.121–1.465) 0.174 0.8 (0.296–2.385) 0.743
matching variables
(gender, disease site, stage)
Adjusted for age and treatment 7.6 (1.2–46) 0.028 0.55 (0.157–1.894) 0.339 1.17 (0.416–3.285) 0.776
modality
HR, hazard ratio; Hp, haptoglobin; 95% CI, 95% confidence interval.
(8). Hp 2-2 stimulates endothelial cell differentiation
and has more angiogenic effects than other Hp phe-
notypes, both in in-vitro and in-vivo models of angio-
genesis (9). Kuhajda et al. (25) showed that decreased
tumor expression of Hp-related protein is associated
with better recurrence-free survival in patients with
breast cancer. The expression of a peak at mass-to-
charge ratio 9198)20, identified as a Hp a-1 chain,
has better recurrence free survival, and 63 breast
cancer patients with Hp 2-2, which lacked an Hp a-1
chain, conferred a poor prognosis (17). Collectively,
these observations may present a possible mecha-
nism for free radical generation and cancer progres-
sion in patients with Hp 2-2.
There are several limitations of this study. First, the
oxidative stress markers and serum Hp concentration
were not measured. Second, the number of cases was
limited. We tried to limit the effect of potential con-
founders by matching analysis. The matching for
three variables known to affect prognosis (gender,
tumor site, and overall stage) renders it more likely to
detect any differences due to Hp polymorphism.
Patients with Hp 2-2 or 2-0 have more locoregional
recurrences and significantly increased HRs in multi-
variate analysis. The Hp genotype may be a prognos-
tic factor in HNSCC.
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